PharmaCom BioVet, Inc. to Provide Novel Canine Cancer Treatment Programs to Meet Exploding Pet Care Demand
November 10 2008 - 8:36AM
Marketwired
PharmaCom BioVet, Inc. (PINKSHEETS: PHMB) is pleased to announce
that their new Canine Cancer Treatment Centers will provide
state-of-the-art cancer technologies to meet the growing demand for
effective treatment of companion animals afflicted with lymphoma
and other forms of cancer.
Concurrent with human trends for increasing life spans,
companion animals are also living longer. According to a recent
report by Tatjana Meerman, Publisher of Packaged Facts, Rockville,
Maryland, "Pets are living longer because their owners are taking
better care of them, both medically and nutritionally." The report
continues by stating that the ever growing bond between pet owners
and their companion animals means, "...an increased willingness
among pet owners to do whatever it takes to keep their pets healthy
and happy for as long as possible."*
However, in the face of this trend, there has been an alarming
lack of adequate options for the treatment of cancer; the number
one cause of death in companion dogs. Statistically, one in three
dogs is diagnosed with cancer at some time in their life, and at
least 50% of those dogs are likely to succumb. The primary reasons
for these staggering statistics are 1) a major deficiency in canine
cancer treatment facilities across the country and, 2) out-dated or
inadequate cancer treatment methodologies available for canine
cancers.
PharmaCom BioVet, Inc. founders, Gary and Sharon Berthold,
experienced this tragedy first hand and decided to do something
about it. As life-long dog lovers and breeders, the Bertholds lost
two of their prize Siberian Huskies to cancer. In their search for
remedies, they discovered a huge void in care centers and treatment
options. That reality inspired them to not only fill the void, but
to advance the cause of creating leading-edge treatment centers
using the latest scientific breakthroughs in cancer treatment.
Among these novel treatment programs are bone marrow transplant
procedures and direct injection liquid Brachytherapy.
Teaming up with IsoTherapeutics Group, LLC of Angleton, Texas,
PharmaCom BioVet, Inc. is poised to support research and help
introduce novel cancer treatment methodologies into its canine
cancer treatment centers, as well as to the veterinary marketplace
as a whole. "Our ultimate goal is to eradicate cancer in companion
animals. We are bringing together the brightest minds in cancer
research and oncology treatment programs to fulfill this goal,"
stated Berthold of PharmaCom BioVet, Inc. "We are excited to join
forces with companies like IsoTherapeutics Group, LLC and
veterinary leaders across the country, in this endeavor to help
companion animals not only live longer, but live healthier,"
concluded Berthold.
About PharmaCom BioVet, Inc.:
PharmaCom BioVet, Inc. is dedicated to advancing the veterinary
care industry for companion animals by establishing
state-of-the-art treatment centers for lymphoma and other forms of
cancer throughout the country. The purpose of these centers is to
help prolong the quality of life for companion animals with cancer
and pursue the potential for complete cure. These centers will also
operate under the philosophy of providing a compassionate care
environment for both companion animal patients and their owners.
For more information, please visit our website
www.PharmaComBioVet.com.
About IsoTherapeutics Group, LLC:
The mission of IsoTherapeutics Group, LLC is to develop novel
diagnostic and therapeutic agents for the treatment of severe
diseases. ITG both develops their own technologies as well as
partners with other companies to help develop pharmaceuticals. Of
special interest are radiopharmaceuticals for oncology. In house
expertise includes synthetic organic chemistry, chelation
chemistry, radiochemistry, diagnostic and therapeutic isotopes,
conjugation chemistry, pharmacokinetics, and small animal research
models. For more information, please visit our website
www.isotherapeutics.com.
DISCLOSURE:
"Safe Harbor" statement under the Private Securities Litigation
Reform Act of 1995: This press release contains forward-looking
statements that are subject to risk and uncertainties, including,
but not limited to, the impact of competitive products, product
demand, market acceptance risks, fluctuations in operating results,
political risk and other risks detailed from time to time in
PharmaCom BioVet, Inc.'s filings with the Securities and Exchange
Commission. These risks could cause PharmaCom BioVet, Inc.'s actual
results to differ materially from those expressed in any
forward-looking statements made by, or on behalf of, PharmaCom
BioVet, Inc.
*Reference: Packaged Facts press release, Friday, October 10,
2008. Packaged Facts is a division of Market Research Group,
Rockville, Maryland.
Contact: Market Ideas, Inc. 877-295-3981 ext. 2
info@marketideasinc.com
PharmaCom BioVet (CE) (USOTC:PHMB)
Historical Stock Chart
From Sep 2024 to Oct 2024
PharmaCom BioVet (CE) (USOTC:PHMB)
Historical Stock Chart
From Oct 2023 to Oct 2024